These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34938290)

  • 41. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
    Wang Y; Wang L; Cao H; Liu C
    J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
    Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
    Wang S; Wang CY; Kuo HK; Peng WJ; Huang JH; Kuo BS; Lin F; Liu YJ; Liu Z; Wu HT; Ding S; Hou KL; Cheng J; Yang YT; Jiang MH; Wang MS; Chen T; Xia WG; Lin E; Hung CH; Chen HJ; Shih Z; Lin YL; Ryan V; Hu MM; Heppner DG; Malherbe DC; Periasamy S; Kuzmina N; Subramani C; Hellerstein M; Monath TP; Rumyantsev A; Bukreyev A; Guirakhoo F
    Emerg Microbes Infect; 2022 Dec; 11(1):2724-2734. PubMed ID: 36287714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
    Geng Q; Tai W; Baxter VK; Shi J; Wan Y; Zhang X; Montgomery SA; Taft-Benz SA; Anderson EJ; Knight AC; Dinnon KH; Leist SR; Baric RS; Shang J; Hong SW; Drelich A; Tseng CK; Jenkins M; Heise M; Du L; Li F
    PLoS Pathog; 2021 Sep; 17(9):e1009897. PubMed ID: 34492082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
    Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
    Front Immunol; 2022; 13():811802. PubMed ID: 35250985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits.
    Park H; Jang MS; Choi JA; Kim W; Kim YB; Kim NH; Choi E; Son HY; Han KH
    Vaccine; 2023 Nov; 41(46):6842-6851. PubMed ID: 37821316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
    Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.
    Ellis D; Brunette N; Crawford KHD; Walls AC; Pham MN; Chen C; Herpoldt KL; Fiala B; Murphy M; Pettie D; Kraft JC; Malone KD; Navarro MJ; Ogohara C; Kepl E; Ravichandran R; Sydeman C; Ahlrichs M; Johnson M; Blackstone A; Carter L; Starr TN; Greaney AJ; Lee KK; Veesler D; Bloom JD; King NP
    Front Immunol; 2021; 12():710263. PubMed ID: 34267764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
    Sonoyama T; Iwata S; Shinkai M; Iwata-Yoshikawa N; Shiwa-Sudo N; Hemmi T; Ainai A; Nagata N; Matsunaga N; Tada Y; Homma T; Omoto S; Yokokawa Shibata R; Igarashi K; Suzuki T; Hasegawa H; Ariyasu M
    Vaccine; 2023 Mar; 41(11):1834-1847. PubMed ID: 36572603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
    Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL
    EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates.
    Zhao H; Wang TC; Li XF; Zhang NN; Li L; Zhou C; Deng YQ; Cao TS; Yang G; Li RT; Huang YJ; Li YG; Zhang YM; Li FX; Zhou YR; Jiang YH; Lu XS; Sun SH; Cheng ML; Gu KP; Zhang M; Ma QQ; Yang X; Ying B; Gao YW; Qin CF
    Signal Transduct Target Ther; 2021 Dec; 6(1):438. PubMed ID: 34952914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
    Mo C; Li X; Wu Q; Fan Y; Liu D; Zhu Y; Yang Y; Liao X; Zhou Z; Zhou L; Li Q; Zhang Q; Liu W; Zhou R; Tian X
    Vaccine; 2023 Nov; 41(46):6863-6869. PubMed ID: 37821314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.